Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir in Neonates Exposed to HIV-1
NCT05406583Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (5 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of Infants Classified as Study Drug-related Safety Failures up to 8 weeks, Proportion of Infants Classified as Safety Failures up to 8 weeks and 3 more. Started Oct 2022; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05406583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406583.